Drugs / PMD-026
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT07379125 | May 2026 → Dec 2028 expected | myelofibrosis | Washington University School of Medicine | Recruiting | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04115306 | Nov 2019 → Dec 2026 expected | secondary malignant neoplasm | Phoenix Molecular Designs | Active not recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PMD-026 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07379125 ↗ |
| Action | Inhibit | “oral inhibitor of ribosomal protein S6 kinase A1 (RSK1)” NCT07379125 ↗ |
| Route | Oral | “Orally Administered PMD-026” NCT04115306 ↗ |
| Target | RPS6KA1 | “inhibitor of ribosomal protein S6 kinase A1 (RSK1)” NCT07379125 ↗ |